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Abstract
In  animals  and mammalian cells,  protein  function can be  analyzed by nucleotide se‐
quence-based methods such as gene knockout,  targeted gene disruption, CRISPR/Cas,
TALEN,  zinc  finger  nucleases,  or  the  RNAi  technique.  Alternatively,  protein  knock‐
down approaches are available based on direct interference of the target protein with
the inhibitor.
Among protein knockdown techniques, the endoplasmic reticulum (ER) intrabodies are
potent molecules for protein knockdown in vitro  and in vivo.  These molecules are in‐
creasingly used for  protein  knockdown in  living cells  and transgenic  mice.  ER intra‐
body  knockdown  technique  is  based  on  the  retention  of  membrane  proteins  and
secretory proteins inside the ER, mediated by recombinant antibody fragments. In con‐
trast  to  nucleotide  sequence-based  methods,  the  intrabody-mediated  knockdown acts
only on the posttranslational level.
In this review, the ER intrabody technology has been compared with the RNAi techni‐
que on the molecular level. The generation of intrabodies and RNAi has also been dis‐
cussed.  Specificity  and  off-target  effects  (OTE)  of  these  molecules  as  well  as  the
therapeutic potential of ER intrabodies and RNAi have been compared.
Keywords: Knockdown techniques, intracellular antibodies, ER intrabodies, RNA inter‐
ference, off-target effects
1. Introduction
For the study of protein function in animals and mammalian cells, DNA-based methods such
as gene knockout, targeted gene disruption, CRISPR/Cas, TALEN, zinc finger nucleases [1],
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
as well as the RNAi technique [2] were proven and reliable tools. Besides the RNAi technique,
approaches with miRNA are also very attractive [3]. Silencing of target mRNA can be achieved
using siRNA, miRNA, or shRNA (Box 1).
Box 1
siRNA
Small interfering RNA (siRNA) are small pieces of double-stranded (ds) RNA, usually about 21 nt long,
with 2-nt-long 3′ overhangs at each end. They can be applied for the interference with the protein
translation by binding to the messenger RNA (mRNA), whereby promoting the degradation or destabi‐
lization of the mRNA.
shRNA
shRNAs form hairpin structures, which consist of a stem region of paired antisense and sense strands,
connected by unpaired nucleotides building a loop. They are converted into siRNAs by the same RNAi
machinery that processes miRNAs.
miRNA
MicroRNAs are small RNA molecules, encoded in the genome of plants and animals. These highly
conserved, ~21-mer RNAs regulate the expression of genes by binding to the 3' untranslated regions (3'-
UTR) of specific mRNAs.
Protein knockdown is possible with small molecule inhibitors including peptides, neutralizing
and intracellular antibodies, and allosteric modulators [4–8]. In addition, aptamers and
intramers, in general short single-stranded DNA or RNA oligonucleotides are also potent
molecules for specific inhibition of small molecules, peptides, proteins, or even whole living
cells [9].
Currently, RNAi is the most often used gene-silencing technique in functional genomics [2].
In this article, we described an emerging protein knockdown technology using intracellular
antibodies (intrabodies) targeted to the ER and compared the advantages and disadvantages
of this promising technique with the RNAi technology. We tried to make scientists, who are
interested in protein research or have very specific protein-related questions, familiar with the
ER intrabody technology [10]. The molecular mechanisms of both methods are different.
RNAi-mediated knockdown is based on the interference of siRNA with mRNA (Figure 1),
whereas the protein knockdown by ER intrabodies is exerted upon binding of a recombinant
antibody fragment to its specific antigen inside the ER [10] (Figure 2).
Intrabodies are recombinant antibody fragments targeted to a cell expressing the specific
antigen. Intracellular binding of the intrabody to the antigen results in inhibition of antigen
function. Moreover, intrabodies can specifically be targeted to subcellular compartments such
RNA Interference138
Figure 1. Principle of the knockdown of transitory proteins using the RNA interference technique. For knockdown
of the mRNA of transitory proteins, transfection with a specific shRNA-expressing plasmid is sufficient. Although by
using the RNA interference technology all kinds of proteins could be targeted, only knockdown of transitory proteins
is illustrated. (1) Specific shRNA is transcribed and processed by the RNase III Dicer-1 enzyme in mammalian cells in
order to form the mature siRNA. (2) The Argonaute 2 protein (Ago2) is loaded with the siRNA and forms together
with additional proteins the RNA-induced silencing complex (RISC), which is a multiprotein complex consisting of ef‐
fector (Argonaute proteins), accessory proteins, and si/miRNA. During the loading of the Argonaute protein, one
strand of the siRNA duplex is discarded. Next, the RISC complex associates with its target mRNA via complementary
base pairing of the siRNA and the target mRNA. In many cases, the recognition site comprises the 3′ untranslated re‐
gions (UTR) of the mRNA. Finally, target binding leads to mRNA degradation or translational inhibition [11]. mRNA
degradation is mediated through the endonuclease activity of the Argonaute proteins. (3) As a result of mRNA knock‐
down, the target protein is not expressed on the cell surface [11].
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Figure 2. Principle of the specific knockdown of transitory proteins with endoplasmic reticulum (ER)-retained in‐
trabodies. In wild-type cells, transitory proteins are transported through the ER and can be further processed (e.g., gly‐
cosylated) in the Golgi apparatus. These proteins could reside in the secretory cell compartments, secreted through the
plasma membrane (PM), or become integrated in the PM as a membrane protein. For functional inhibition of these pro‐
teins, transfection with an ER intrabody expressing plasmid is sufficient. The intrabody construct consists of an N-ter‐
minal secretion sequence for the translocation in the ER (leader sequence) and the C-terminal retention signal (KDEL).
(1) The intrabody inside of the ER binds to the target protein. This complex of antibody and target protein is further
processed and transported through the secretory pathway. (2) In the cis-cisterna of the Golgi stack, the hERD2 receptor
binds to the KDEL sequence and (3) initiates the retrograde transport back to the ER compartment. This continuous
binding of the intrabody and retrograde transport prevents the target protein to reach its localization where it normal‐
ly acts. (4) The accumulated intrabody–antigen complex in the ER might be transported into the cytoplasm, where it is
marked for degradation by the 26S proteasome [12, 13]. Böldicke and Burgdorf have shown that an anti-toll-like recep‐
tor 2 (TLR2) ER intrabody is degraded by the proteasome (unpublished data).
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as the nucleus, cytoplasm, mitochondria, or ER [10] (Box 2). Currently, the most used and
promising intrabodies are the ER intrabodies, because of the correct folding in the oxidative
environment of the ER [14]. This contrasts with cytosolic intrabodies, in which disulfide
bridges are not formed in the reducing environment of the cytoplasm [15, 16].
Box 2
Intrabodies are intracellularly expressed recombinant antibody fragments, which specifically inhibit the
function of target proteins produced in the same cell [10].
ER Intrabodies retain their corresponding antigen inside the ER by inhibiting the translocation of the
antigen to the cell compartment where it normally acts.
Cytosolic Intrabodies are expressed in the cytoplasm. They inactivate their targets or interfere with the
binding of the target protein to its corresponding binding partner.
The effect of ER intrabodies is based on retention of proteins passing the secretory pathway.
Secretory proteins, membrane proteins, and even Golgi or endosomal-located proteins can be
targeted [17–19], which cannot be reached by classical antibodies, due to the extracellular
presence. Successful functional knockdown was achieved for oncogenic receptors, viral
proteins for preventing virus assembly, cellular virus receptors to block virus entry, and
receptors of the immune system as well as of the nervous system [20–24].
The format of expressed intrabodies is, in general, the single-chain variable fragment (scFv) or
less common the antigen-binding fragment (Fab) [25]. The only prerequisite of ER intrabodies
is the efficient binding to the antigen, and the method to select and generate an ER intrabody
is greatly simplified by phage display. On the contrary, functional cytoplasmic intrabodies
have to inactivate the antigen or have to interfere with the binding of the target protein to its
corresponding binding partner [10].
The starting material for construction of an ER intrabody is an scFv or Fab, which can be
obtained by amplification of the variable domains from a hybridoma clone [26], or scFv
fragments can be selected from phage or yeast display [27, 28].
Early attempts using the intrabody approach failed frequently due to the lack of reliable
techniques for the identification of the correct functional antibody sequence from a hybridoma
clone. The genes of the variable domains for construction of recombinant antibody fragments
can be amplified from hybridoma clones using mixtures of consensus primers [29]. This
approach was used in the beginning. As hybridoma cells could secrete several different
antibodies, it was sometimes difficult to isolate the correct functional sequences of the variable
domains. Presently, with reliable protein sequencing techniques, next generation of DNA
sequencing and optimized consensus primer sequences, the functional antibody DNA can
much better be identified. Furthermore, optimized strategies for amplification of the correct
functional antibody sequence are available [30–32].
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In the case of using in vitro display systems, like phage or yeast cell surface display, the selected
scFv fragment has only to be cloned into the ER-targeting vector. For preliminary characteri‐
zation of the intrabody function, co-transfection of the intrabody expression plasmid with the
corresponding antigen expression plasmid into HEK 293 cells is sufficient and followed by co-
immunoprecipitation and immunofluorescence analysis [33].
In contrast to the ER intrabody technology, the advantage of the RNAi is that it can be applied
for almost every mRNA and also non-coding RNAs. Here, we further compared the RNAi
with the intrabody technology, regarding specificity, off-target effects, and therapeutic
approaches.
2. Intracellular intrabodies versus RNA interference
2.1. Generation of ER intrabodies
The prerequisite for generating intrabodies is the availability of a hybridoma antibody clone
or scFv/Fab fragments selected from in vitro display systems [10]. Starting from a hybrido‐
ma clone, the variable domains of the heavy and light chain are amplified by PCR from the
cDNA. This can be achieved by (1) PCR amplification using consensus primer [29, 34–36],
(2) rapid amplification of cDNA ends (RACE) [30], (3) PCR amplification using adaptor-
ligated cDNA [31],  or (4) inverse PCR with constant region heavy chain and light chain
primer, amplifying the corresponding antibody sequence from circularized double-strand‐
ed cDNA [32] (Figure 3 A).
In most cases, using consensus primers is a fast and efficient approach for amplification of the
correct functional antibody sequence from a hybridoma clone. However, less-common non-
consensus antibody sequences cannot be amplified and primer mismatching could be a
problem. Approaches (no. 2–4 shown in Figure 3) for amplifying the variable antibody
domains are more time-consuming; however, the correct functional antibody gene sequence
can be obtained. The variable domains are compiled by assembly PCR, linking both variable
domains together by a short flexible linker sequence, for example (Gly4Ser)3, resulting in the
scFv fragment. Next, the scFv fragment will be cloned into the ER targeting vector, providing
the ER signal sequence, an myc tag for detection of intrabody, and the KDEL retention sequence
localized at the C-terminus of the intrabody gene [26].
Following the in vitro display pipeline, an scFv fragment or Fab fragment selected by phage
or yeast cell surface display can directly be cloned into the ER targeting vector. Most recombi‐
nant antibody fragments in the scFv or Fab format are selected by phage display or also the
frequently used yeast cell surface display [27, 28, 41]. Other in vitro display systems are
bacterial, mammalian cell surface display, or ribosome display [42–44]. Cytoplasmic intra‐
bodies are generated from hybridoma clones or scFv/Fab fragments from in vitro display
libraries in a similar way and cloned into an appropriate cytosolic targeting vector [10]. The
main difference in comparison to ER intrabodies is that cytosolic intrabodies have to demon‐
strate neutralizing activity, and furthermore stable folding antibody fragments have to be
selected [10].
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Figure 3. Generation of intrabody and RNA interference knockdown constructs. (A) Generation of intrabody knock‐
down vectors. The scFv fragment could be either cloned from hybridoma cell lines or selected from huge human naive
phage display libraries. The antibody variable domain of the light chain (VL) and heavy chain (VH) is amplified from
cDNA using consensus primer mixtures (1), 5′ adapter-ligated PCR or rapid amplification of cDNA ends (RACE) (2) or
with constant domain-specific primer from circularized cDNA (3). The antibody VL and VH genes are assembled as
scFv by fusing both domains with a flexible (Gly4Ser)3-linker sequence and cloned into the ER targeting intrabody vec‐
tor. The scFvs are cloned between an upstream secretion signal and a downstream retention sequence (KDEL). Using
the phage display system, selected scFvs can directly be cloned into the intrabody vector in one cloning step. Shown is
an ER-targeting vector. (B) Generation of siRNA/shRNA/miRNA knockdown vectors. Rational in silico design of siR‐
NA, shRNA, or miRNA mimics using software algorithms like those mentioned in Ref. [37] or in Ref. [38], a recent
publication, deduced from the target cDNA. The algorithms are designed to select appropriated sequences by means
of empiric criteria. Main criteria are an siRNA length of 19–21 nucleotides (nt) in conjunction with 2 nt overhangs at
ER-targeted Intrabodies Mediating Specific In Vivo Knockdown of Transitory Proteins in Comparison to RNAi
http://dx.doi.org/10.5772/62103
143
their 3′ ends, as well as thermodynamic properties of target mRNA hybridization. Rational design can be expanded by
testing in silico the potential off-target effects of the designed sequences by using genome-wide enrichment of seed se‐
quence matches (GESS) [39] or Haystack [40]. Designed sequences are chemically synthesized and cloned into appro‐
priate mammalian or viral knockdown expression vectors. Alternatively, siRNA can be used for direct cell transfection.
The siRNA/shRNA/miRNA sequences originated from rational design are screened for effective processing, specific
knockdown capabilities, and potential off-target effects. Corresponding clones are selected, and for most applications
3–4 different targeting sequences were chosen and theses libraries are used for the RNA interference knockdown. ER:
endoplasmic reticulum, CDS: coding DNA sequence, p:promoter.
2.2. Generation of siRNA, miRNA, and shRNA
In order to generate siRNAs for a specific target, only the mRNA information about the target
sequence is needed [45] (Figure 3 B). siRNA-mediated mRNA knockdown can be performed
in several ways. In general, cells can directly be transfected with siRNA, using transfection
reagents like lipofectamine. Cells can also be transfected using siRNA/shRNA/miRNA-
expressing plasmids or viral vectors. Long-lasting gene silencing can be achieved with shRNAs
expressed from stably transfected plasmids or from integrated retro- or lentiviral vectors [46].
Several approaches exist for RNA interference-mediated knockdown, the principle workflow
of in silico design, screening, and selection of siRNA/shRNA/miRNA, with best knockdown
properties shown in Figure 3 B. Currently, software algorithms mentioned in Ref. [37] or [38]
can help to find the appropriate knockdown sequences of 19–21 nt length siRNA by analysis
of the optimal thermodynamic properties of mRNA hybridization. Potential off-target effects
can be reduced by in silico optimization with GESS [39] or Haystack [40]. Resulting siRNA/
shRNA/miRNA sequences are tested for effective processing, specific knockdown capability,
and low off-target effects.
2.3. Stability
Intrabodies are stably expressed inside the ER [14], whereas most cytosolic intrabodies are not
correctly folded [15, 16]. On the other hand, siRNA can be cleaved by nucleases, present in the
blood serum and cellular cytoplasm.
2.4. Specificity and Off-Target Effects (OTE)
For the knockdown of distinct target proteins, the specificity of the process is crucial. Other‐
wise, the resulting phenotypes of the induced knockdown experiment might be superimposed
with off-target effects. The specificity of the RNAi and the ER intrabody knockdown technique
is the main difference between them.
Intrabodies, which are also known as intracellular antibodies, are generated from monoclonal
antibodies (mAbs) and phage or yeast antibody repertoires. Intrabodies are very specific to
their targets due to antibody–antigen interactions.
The high specificity of ER intrabodies has been demonstrated for the specific knockdown of
members of the TLRs. The knockdown of toll-like receptor 2 (TLR2) and TLR9, which functions
as a part of the innate immunity and recognizes pathogen-associated molecular patterns
(PAMP), did not influence the expression of other TLRs. The developed anti-TLR2 intrabody
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did not inhibit TLR3-, TLR4-, and TLR9-driven signal transduction [33] and the anti-TLR9
intrabody did not inhibit TLR3-, TLR4-, TLR7-, and TLR8-driven signaling, respectively [18].
Stress response induction in the endoplasmic reticulum (ER), due to the accumulation of
retained and partially unfolded target proteins upon intrabody–antigen complex formation,
was analyzed by measuring the unfolded protein response (UPR) for an overexpressed anti-
p75NTR ER intrabody and could not be proven [24]. No off-target effects of expressed
intrabodies are known yet, particularly any activation of the immune system.
On the other hand, unspecific silencing is a major problem using RNAi-mediated gene
silencing, due to the expression of short-interfering RNA sequences, such as miRNA, siRNA,
shRNA, or dsRNA [47]. The short seed region of these silencing RNAs recognizes and
hybridizes with 2–8 nt to the target mRNA. Even with specific alignment software, it is
practically impossible to exclude any possible transcript, which aligns with the target seed
sequence, because statistically the chance is high to have the same sequence or secondary
structure in other non-target mRNA transcripts too. However, at least software algorithms
such as GESS [39] and Haystack [40] are able to predict potential off-targeted genes. By
computer-aided optimization of the miRNA, siRNA, or shRNA, the OTEs can be reduced to
a minimum.
siRNA can bind to TLR3, TLR7, and TLR8, resulting in secretion of type I interferon and pro-
inflammatory cytokines [48–50]. Aberrant expression of up to more than 1000 genes has also
been described [51].
Fortunately, some progress has been made in the repression of the RNAi-induced immune
response. When siRNA is in vitro transcribed by the T7 polymerase, a 5′-triphosphate group
is added. The 5′ triphosphate is recognized by the innate immunity, and it activates the type
I interferon response. This can be prevented by chemical synthesis of siRNA, which misses the
5′-triphosphate group. Furthermore, the siRNA molecules can be modified by adding 2′-O-
methyl groups, in order to reduce the recognition by toll-like receptors (TLRs) [52]. Interest‐
ingly, this modification additionally hampers degradation of the siRNA by RNases, leading
to an increase in serum half-life [53]. Finally, strong destabilizing unlocked nucleic acids
(UNAs), which were altered to have an acyclic ribose, also reduce the recognition by TLRs [54].
The specific suppression of one allele in heterozygous genes is of concern in dominantly
inherited genetic disorders. Huntington’s disease (HD) is caused by a dominant mutation of
the huntingtin protein (Htt) and an excellent target for the examination of allele-specific
knockdown of the mutated Htt, with high therapeutic potential. Huntington’s disease is based
on a long stretch of CAG triplets on one disease-caused allele [55]. Most of the patients are
heterozygous for the htt gene mutation and 48% of the American and European HD patients
are heterozygous at a single nucleotide polymorphism (SNP) site, making this genetic disease
a bono fide target for specific protein knockdown. Approaches to inhibit the appearance of
Huntington’s disease is silencing of wild type and mutant Htt or silencing of only the disease-
causing allele.
Although it was found in HD mice that co-silencing of wild type and mutant Htt provides
therapeutic benefit, nothing is known of such a long-term suppression of huntingtin [56]. Thus,
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the effect and safety over decades have yet to be proven in clinical trials. Therefore, there is
still a need for high allele-specific inhibition of the mutant Htt protein, which is toxic due to
an expanded polyglutamine (polyQ) motif (CAG motif). Targeting of the CAG motif is not
selective for the mutant allele and affected both alleles. Genotyping of the Huntington’s disease
patients resulted in three single nucleotide polymorphisms (SNP) in huntingtin [57]. Therefore,
an alternative strategy when using RNAi is targeting a single nucleotide mutation localized
in the disease-caused sequence [58]. Furthermore, targeting of the mutant huntingtin SNPs or
the expanded CAG motif by designed artificial miRNAs was recently demonstrated in vitro,
using an allele-specific reporter system and in vivo in a transgenic mouse model [59].
For the RNAi technique, it is possible to discriminate between very similar targets with a
specific reduction on the RNA and protein level [58, 60, 61]. However, there are still some
concerns and limitations. The RNAi-mediated allele-specific knockdown may result in a broad
off-targeting and therefore has to be further evaluated in appropriate preclinical model
systems [62]. Using both target strategies, CAG motif and prevalent mutant SNPs, in the case
of huntingtin, the wild-type allele is also affected by the knockdown, and the knockdown ratio
between the wild type and mutant allele remains unsatisfactory. Furthermore, the shift to in
vivo delivery systems can have a substantial impact on the specificity, as was demonstrated in
the mouse model [59]. Next, a limited expression of the miRNA vectors is important to avoid
saturation of the miRNA processing machinery, as the selectivity seems to be reduced when
miRNAs are highly expressed in vivo [59].
Different alleles can also be targeted and discriminated using specific intracellular antibodies
(intrabodies) and represent a valuable alternative to RNA interference. Intrabodies targeting,
for example, huntingtin have to recognize an epitope common in most disease-associated
huntingtin SNP forms, which also has to be different in the translated amino acid between the
mutant and wild-type allele. Alternatively, they could target the expanded polyglutamine
(polyQ) motif associated with misfolding and aggregation [63]. Furthermore, cytoplasmic
intrabodies have been developed, which efficiently inhibited aggregation of mutant HD [64].
Interestingly, a disulfide bond-free single-domain intracellular antibody with high affinity was
developed after affinity maturation [65] from a specific anti-HD scFv fragment, demonstrating
the power of antibody engineering.
For the allele-specific knockdown, the intrabody technology utilizes the high specificity of
monoclonal antibodies, with no or low concerns about off-target effects and activation of the
immune system. In the case of huntingtin, no RNAi approach was able to discriminate
effectively between the wild-type and mutant expanded polyglutamine stretch [59]. Here,
intracellular antibodies could, in principle, recognize different conformational epitopes
formed by polyglutamine and might be able to discriminate between the length of the polyQ
motifs [63]. However, in the case of the cytoplasmic huntingtin protein, it is more difficult to
generate and select cyto-intrabodies, due to the reducing environment of the cytoplasm. In
general, the allele-specific knockdown strategy should be also applied with ER intrabodies.
The kind of mismatches introduced into siRNAs or artificial miRNAs, in order to increase allele
specificity for preference of the mutant allele, can differ. Purine-to-purine mismatches, for
example, are more effective than purine-to-pyrimidine mismatches. This limitation can be
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overcome by introduction of a second mismatch, preferentially into the seed or cleavage region
of the siRNA/miRNA [59]. Using a set of SNP sites, common in disease-associated alleles, might
enable reaching many patients [57], but it is hard to access the whole population. For those
genotypes that could not be cured by using mutant SNP-targeting siRNA, intrabody-mediated
protein knockdown, recognizing a prevalent mutant epitope could be superior. Whereby, in
the case of SNPs due to the posttranslational targeting, the intrabody technology demonstrates
one of its weaknesses. Discrimination between mutant and wild-type SNP could only be
achieved when the mutant SNP induces a change of the encoded amino acid. In addition,
mutant SNPs in introns and untranslated regions (UTR) cannot be addressed, as it is in the
case of HD.
Features Intrabodies siRNA, shRNA,miRNA
Requirements
Monoclonal antibody
or scFv/Fab selected by phage or yeast cell
surface display
Sequence of the mRNA
Very high specificity
to the antigen + Off-target effects
Stability Stable in the ER Susceptibilityto nucleases
Inhibition of
post-translational
modifications
+ -
Inhibition of
splice variants + +
Inhibition of several
protein isoforms
with one intrabody
or siRNA
+ +
Targeting of specific
protein domains + +
High-throughput
screening - +
In vivo knockdown + +
Table 1. Intrabodies versus siRNA
2.5. High-throughput screening
Oligonucleotide and cDNA microarrays can be applied for simultaneous quantitative moni‐
toring of gene expression of thousands of genes [66]. A combination of cDNA microarrays and
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RNA interference was used to validate upregulated genes, playing an important role in cancer
development [67]. In this case, a pre-screening with cDNA microarrays is performed followed
by silencing of selected upregulated mRNAs using RNAi. This might also be possible with
intrabodies.
Although high-throughput RNAi screening is very useful in order to validate new genes
involved in cancer pathogenesis or infection processes [68, 69], such high-throughput screen‐
ing is not possible with intrabodies.
2.6. Therapeutic potential of siRNA and ER intrabodies
The therapeutic potential of siRNA and ER intrabodies has been shown in different mouse
models [70–73]. It has been shown that siRNA protected mice from fulminant hepatitis [74],
viral infection [75], sepsis [76], tumor growth [77], and macular degeneration [78]. In these
mouse models, synthetic siRNA was delivered systemically, peritoneally, or subretinally.
Furthermore, in an Alzheimer’s and spinocerebellar ataxia disease-related mouse model,
RNAi suppresses the expression of amyloid-β peptide or ataxia, respectively [79, 80]. In these
mouse models, target-specific RNAi was virally delivered using adeno-associated virus or
Herpes simplex virus. Interestingly, the knockdown of angiopoietin-2 mRNA in a mouse
model with pancreatic carcinoma and xenotransplantation suppresses metastasis and down‐
regulates metalloproteinase-2 [81].
Many ER intrabodies have shown therapeutic potential against relevant targets in cancer,
infection, and brain diseases, for example, ErbB-2, EGFR, VEGFR-2, Tie-2, VEGFR-2 × Tie-2,
metalloproteinases MMP-2, MMP-9, E7 oncoprotein of human papillomavirus, CCR5, TLR2,
TLR9, and amyloid-β protein [18, 33, 82–90]. Nevertheless, only four of these antigens have
been applied in xenograft tumor mouse models so far, using an anti-Tie intrabody [85], a
bispecific VEGFR-2 × Tie-2 intrabody [86], an anti-amyloid-β protein intrabody in an Alz‐
heimer’s disease mouse model [90], and an anti-E7 oncoprotein intrabody in a mouse infection
model with human papillomavirus [89]. Intrabody delivery was performed via adenovirus,
adeno-associated virus, and retrovirus, respectively.
2.6.1. Transgenic mice
Transgenic RNAi mouse against p120-Ras GTPase-activating protein [91] and cytokine-
activated IκB kinase 1 (IKK1) has been established [92]. Furthermore, RNAi transgenic mice
and non-germline genetically engineered RNAi cancer mouse models were established [93].
In contrast to constitutive RNAi transgenic mice, generation of conditional RNAi in mice is
also possible [94].
Recently, two transgenic ER intrabody mice have been generated against VCAM and gelsolin
[71, 72]. In addition, a transgenic mouse expressing an anti-EVH1 intrabody has been pub‐
lished [73]. However, the inhibitory results obtained with these mice have been criticized
because the intrabody was directed to the secretory pathway, but confusingly recognized a
cytosolic protein [95]. Interestingly, the transgenic VCAM intrabody mouse was viable in
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contrast to the lethal knockout mice generated by targeted homologous recombination [96].
The intrabody mice were deficient in VCAM-1 cell surface expression.
2.6.2. Clinical approaches
Different clinical approaches have been performed with siRNA. RNAi-based clinical trials are
ongoing (phase I–III) [62, 97]. For example, a Bevasiranib RNAi targeting VEGF has been
applied to heal macular degeneration [98] and RNAi targeting the RSV nucleocapsid SPC3649
has shown significant anti-viral activity [99].
In comparison to the RNAi, only one example of an ER intrabody targeting erbB-2 has been
applied in a clinical phase I study [82]. As demonstrated, none of the patients treated in this
study exhibited a dramatic clinical benefit.
Both methods share the limitations of viral and non-viral delivery methods. Using integrating
vectors, insertional mutagenesis is still the main problem [100]. Concerning non-viral delivery
methods, lipid-based and peptide polymer-based delivery systems have been applied [101].
However, for some diseases like HD, the non-neurotropic feature of many delivery systems
and the lack of passing the blood–brain barrier (BBB) remain problematic.
Cell- and tissue-specific targeting is also always a concern; however, transductional and
transcriptional targeting is promising [102]. Tissue-specific carrier for siRNA includes
aptamers, antibodies, peptides, proteins, and oligonucleotide agonists [101]. Referring to ER
intrabodies, the use of mRNA in clinical approaches is promising [103].
2.7. Other features
Intrabodies are able to inhibit posttranslational modifications, such as phosphorylation sites
[104, 105]. This is not possible using RNAi. Besides the high specificity of intrabodies, this is
an important advantage of intrabodies over RNAi.
Recently, single-stranded siRNA was used to suppress the spliced variants of proteins [106].
This might also be possible with specific intrabodies (Table 1). In addition, targeting of specific
protein domains and isomers of a protein might also be feasible. For example, miRNA
suppresses specifically an oncogenic isoform [107]. Intriguingly, the suppression of different
protein isoforms with only one intrabody or one siRNA, recognizing a common epitope within
all isoforms, might be possible, for example, the knockdown of all interferon alpha isoforms
(13 different subtypes in human).
2.8. miRNA
It is known that miRNA influences tumorigenesis [3], and therefore miRNA and combined
miRNA/siRNA pharmacological approaches are attractive [108]. miRNA has been applied in
cancer mouse models as for lymphoid malignancies [109]. Furthermore, important studies
using miRNA has been performed for diagnosis, prognosis, and prediction of cancer [108].
One of the most developed microRNA-based candidates is MRX34, a miR-34 mimetic that
restores the function of miR-34 in cancer cells [110], which is applied in an ongoing multicenter
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phase I clinical trial. The repression of expression of several potential miR-34 target oncogenes
was demonstrated [111]. Finally, miRNAs can be used to reprogram somatic cells into
pluripotent stem cells [112]. However, siRNA and miRNA share the same silencing machinery
and microRNA causes also off-target effects [113].
3. Conclusions and perspectives
siRNA and ER intrabody technology are both efficient knockdown techniques. siRNA is acting
on the mRNA level, whereas ER intrabodies are acting on the protein level. The strength of
the RNAi technology results from the possibility that nearly all mRNAs of a cell can be targeted.
Currently, the knockdown of proteins mediated by intrabodies is most promising with ER
intrabodies, because they are correctly folded inside the ER and can be generated more easily
than in the past. Because of the availability of many new scFv fragments, generated by research
consortia, one cloning step is sufficient to convert selected scFv fragments into ER intrabodies.
Stable cytosolic intrabodies have to be selected with considerable effort. Two approaches are
successful and reliable: the intracellular antibody capture technology, based on an antigen-
dependent two-hybrid system [114] and single-domain antibodies [115], which are stably
folded in a reducing environment for inhibition of cytoplasmic proteins. Single-domain
antibodies comprise only one V region, the variable domain of the heavy or light chain. Most
successfully applied are camelid single-domain antibodies (VHHs) [115–118]. Alternatively,
human VL and VH domains are also potent molecules and their successful construction is
ongoing [119, 120].
The number of ER intrabodies will increase due to the fact that international research consortia
as the “Affinomics” initiative [121] in the European Union and similar initiatives in the United
States have already generated several thousands of recombinant antibodies, including the V-
region genes, which can be used to build up a new repertoire of intrabodies. Using this pipeline,
the duration for development of intrabodies is similar to that of siRNA/shRNA/miRNAs. In
the future, scFvs against very valuable disease-related targets have to be provided.
The main advantage of intrabodies is their specificity, no off-target effects, and posttransla‐
tional modification inhibition. The specificity of an intrabody can be estimated by immuno‐
assays such as ELISA, flow cytometry, and immunoprecipitation. On the contrary, the
specificity and off-target effects of RNAi are often more difficult to predict.
Conferring to in vivo application, RNAi has been currently applied predominantly in phase 1
and 2 studies [62, 97]. In the future, the success of clinical approaches using RNAi and ER
intrabodies is dependent on the development of safe viral vectors and the development of non-
viral vectors possessing high transfection efficiency [122].
Two attractive applications of RNAi, hardly to perform with ER intrabodies, are genome-wide
screening [68, 69] and reprogramming of somatic cells into pluripotent stem cells [112].
Thus, the ER intrabody approach has demonstrated its huge potential for in vitro and in vivo
analysis of protein function [10]. The ER intrabody technique can complement the RNAi
RNA Interference150
technique in cases where siRNA, shRNA, and miRNA molecules demonstrate unwanted
unspecificity and off-target effects.
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